Should I buy or sell BriaCell Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares. View BCTX analyst ratings or view top-rated stocks .

What is BriaCell Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price objectives for BriaCell Therapeutics' stock. Their BCTX share price targets range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 323.7% from the stock's current price. View analysts price targets for BCTX or view top-rated stocks among Wall Street analysts .

How have BCTX shares performed in 2023?

BriaCell Therapeutics' stock was trading at $4.37 on January 1st, 2023. Since then, BCTX stock has increased by 8.0% and is now trading at $4.72. View the best growth stocks for 2023 here .

When is BriaCell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 13th 2023. View our BCTX earnings forecast .

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) released its quarterly earnings data on Wednesday, October, 25th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.25.

When did BriaCell Therapeutics IPO?

(BCTX) raised $15 million in an initial public offering (IPO) on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

Who are BriaCell Therapeutics' major shareholders?

BriaCell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include K.J. Harrison & Partners Inc (0.41%), K2 Principal Fund L.P. (0.16%), Concord Wealth Partners (0.07%), Sabby Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of BriaCell Therapeutics?

Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

BriaCell Therapeutics (BCTX) Stock Price, News & Analysis

$4.72

-0.18 (-3.67%)

(As of 12/8/2023 08:56 PM ET)

Compare

Today's Range: $4.64
▼
$4.97
50-Day Range: $3.79
▼
$5.97
52-Week Range: $3.67
▼
$8.10

Volume: 79,200 shs
Average Volume: 129,736 shs
Market Capitalization: $75.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

BriaCell Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 323.7% Upside
$20.00 Price Target
Short Interest: Bearish
7.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.14) to ($1.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

598th out of 942 stocks

Pharmaceutical Preparations Industry

275th out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
BriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.00, BriaCell Therapeutics has a forecasted upside of 323.7% from its current price of $4.72.
Amount of Analyst Coverage
BriaCell Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.00% of the float of BriaCell Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
BriaCell Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
Change versus previous month
Short interest in BriaCell Therapeutics has recently increased by 3.78%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
BriaCell Therapeutics does not currently pay a dividend.
Dividend Growth
BriaCell Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCTX.

3.7

News and Social Media Coverage

News Sentiment
BriaCell Therapeutics has a news sentiment score of 1.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.
Search Interest
2 people have searched for BCTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.20% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 17.33% of the stock of BriaCell Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BriaCell Therapeutics are expected to grow in the coming year, from ($1.14) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BriaCell Therapeutics is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BriaCell Therapeutics is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About BriaCell Therapeutics Stock (NASDAQ:BCTX)

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for the treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BCTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCTX Stock News Headlines

December 6, 2023 | finance.yahoo.com

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

November 8, 2023 | finance.yahoo.com

BCTX: November 2023 SITC Poster

December 11, 2023 | Edge On The Street (Ad)

The Battery Metal Nobody Told You About

According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."

November 4, 2023 | morningstar.com

BriaCell Therapeutics Corp Ordinary Shares - New BCTX

November 1, 2023 | finance.yahoo.com

BCTX: Year in Review

October 24, 2023 | morningstar.com

BriaCell Therapeutics Corp Ordinary Shares - New

October 11, 2023 | finance.yahoo.com

BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

August 31, 2023 | finance.yahoo.com

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

December 11, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

August 31, 2023 | finance.yahoo.com

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer

August 28, 2023 | bizjournals.com

BriaCell receives court approval to launch spinoff aimed at accelerating cancer drug development

July 10, 2023 | finance.yahoo.com

BCTX: Pivotal Study Protocol Cleared

June 28, 2023 | benzinga.com

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target

June 27, 2023 | baystreet.ca

Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

June 27, 2023 | finance.yahoo.com

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

May 25, 2023 | baystreet.ca

There are Positive Developments in the Treatment of Metastatic Breast Cancer

May 15, 2023 | baystreet.ca

Five Impressive Metastatic Cancer Treatment Stocks to Own Today

May 15, 2023 | finance.yahoo.com

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

April 27, 2023 | finance.yahoo.com

BCTX: Posters Galore at AACR

April 10, 2023 | finance.yahoo.com

BriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth Plans

March 30, 2023 | seekingalpha.com

BriaCell plans spin-out of some pre-clinical assets into new entity

March 24, 2023 | finanznachrichten.de

USA News Group: Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

March 14, 2023 | finance.yahoo.com

A BriaCell Therapeutics Corp. (TSE:BCT) insider increased their holdings by 20% last year

March 9, 2023 | finance.yahoo.com

BCTX: 82% Survival Benefit

February 28, 2023 | seekingalpha.com

BCTX BriaCell Therapeutics Corp.

January 20, 2023 | finance.yahoo.com

Lab Notes: Amicus founder gets national honor; Capstan and Code Bio land on list of companies to watch

December 19, 2022 | finance.yahoo.com

BCTX: Down in San Antone

See More Headlines

Receive BCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/25/2023
Today: 12/11/2023
Next Earnings (Estimated): 12/13/2023
Fiscal Year End: 7/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCTX
CUSIP: N/A
CIK: 1610820
Web: www.briacell.com
Phone: (604) 921-1810
Fax: 604-921-1898
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.00
High Stock Price Target: $20.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +323.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,300,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -997.24%
Return on Assets: -62.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.96
Quick Ratio: 14.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.24) per share
Price / Book: -19.67

Miscellaneous

Outstanding Shares: 15,982,000
Free Float: 12,434,000
Market Cap: $75.44 million
Optionable: Not Optionable
Beta: 1.34

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

William V. Williams
President, Chief Executive Officer & Director
Gadi Levin
Chief Financial Officer & Secretary
Miguel A. Lopez-Lago
Chief Scientific Officer
Guiseppe Del Priore
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BriaCell Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares.
View BCTX analyst ratings or view top-rated stocks.
What is BriaCell Therapeutics' stock price target for 2024?: 1 brokers have issued twelve-month price objectives for BriaCell Therapeutics' stock. Their BCTX share price targets range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 323.7% from the stock's current price.
View analysts price targets for BCTX or view top-rated stocks among Wall Street analysts.
How have BCTX shares performed in 2023?: BriaCell Therapeutics' stock was trading at $4.37 on January 1st, 2023. Since then, BCTX stock has increased by 8.0% and is now trading at $4.72.
View the best growth stocks for 2023 here.
When is BriaCell Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 13th 2023.
View our BCTX earnings forecast.

How were BriaCell Therapeutics' earnings last quarter?: BriaCell Therapeutics Corp. (NASDAQ:BCTX) released its quarterly earnings data on Wednesday, October, 25th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.25.
When did BriaCell Therapeutics IPO?: (BCTX) raised $15 million in an initial public offering (IPO) on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.
Who are BriaCell Therapeutics' major shareholders?: BriaCell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include K.J. Harrison & Partners Inc (0.41%), K2 Principal Fund L.P. (0.16%), Concord Wealth Partners (0.07%), Sabby Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of BriaCell Therapeutics?: Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BCTX) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial